Lisata Therapeutics

Actuate Therapeutics' elraglusib reduced death risk by 37% in a Phase I/II metastatic pancreatic cancer trial, doubling one-year survival rate to 43.6% in the treatment arm vs 22.5% in the control arm. The company plans a Phase III study based on these encouraging results.

Lisata Therapeutics completed enrollment in Phase 1b/2a CENDIFOX trial evaluating certepetide with FOLFIRINOX for pancreatic, colon, and appendiceal cancers. The trial, led by Dr. Anup Kasi at KU Cancer Center, aims to assess safety and efficacy, with 66 patients enrolled. Results expected in 2025.

Emily Jarvie, a journalist with a background in political and business reporting, joined Proactive in 2022. Proactive, a global financial news provider, operates in key finance hubs and covers various markets. The company uses technology to enhance workflows but maintains human authorship for all content.

Lisata Therapeutics wins 'Specialized BioTherapeutics Company of the Year' at the 4th annual BioTech Breakthrough Awards for its innovative therapies targeting advanced solid tumors, leveraging its CendR Platform® technology and investigational drug certepetide.

Emily Jarvie, a seasoned journalist, transitioned from political reporting in Australia to covering business and psychedelics in Canada before joining Proactive in 2022. Proactive, a global financial news provider, operates in major finance hubs and specializes in medium and small-cap markets, offering insights in various sectors. The company uses technology to enhance content creation, ensuring all published content is human-authored.

BioTech Breakthrough announces 4th annual awards recognizing top life sciences and biotechnology innovations, with winners including Leyden Labs, Rocket Pharmaceuticals, Phathom Pharmaceuticals, and more.

Lisata Therapeutics wins 'Specialized BioTherapeutics Company of the Year' at the 4th annual BioTech Breakthrough Awards for its innovative therapies targeting advanced solid tumors, including certepetide, which has shown efficacy in pancreatic cancer and received FDA designations.

BioTech Breakthrough announced winners of its 4th annual awards, recognizing top biotech companies and innovations in areas like BioPharma, Genomics, Therapeutics, and AI. The program attracted thousands of nominations from 14 countries, highlighting advancements in biological sciences and AI, such as CRISPR and precision medicine.

Emily Jarvie, a journalist with a background in political and business reporting, joined Proactive in 2022. Proactive provides global investment news, covering various sectors and using technology to enhance content production, while maintaining human authorship.

DelveInsight's 'Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024' report details 20+ companies developing therapies, including Orchard Therapeutics, Lisata Therapeutics, Genenta science, and Editas Medicine. Key therapies in clinical trials are OTL-204, OTL-105, LSTA201, Temferon, and EDIT-301. The report covers mechanism of action, route of administration, and market dynamics.